Transforming Growth Factor beta3 (TGF beta 3)

A TGF-beta subtype that plays role in regulating epithelial-mesenchymal interaction during embryonic development. It is synthesized as a precursor molecule that is cleaved to form mature TGF-beta3 and TGF-beta3 latency-associated peptide. The association of the cleavage products results in the formation a latent protein which must be activated to bind its receptor.
Also Known As:
TGF beta 3; TGF-beta-3; TGF-beta3 Latency-Associated Protein; TGF-beta3LAP; TGFB3; Transforming Growth Factor beta 3 Latency Associated Peptide; Latency-Associated Protein, TGF-beta3; TGF beta3; TGF beta3 Latency Associated Protein; TGF-beta3
Networked: 301 relevant articles (10 outcomes, 49 trials/studies)

Relationship Network

Bio-Agent Context: Research Results


1. Ferguson, Mark W J: 5 articles (08/2009 - 10/2005)
2. O'Kane, Sharon: 5 articles (08/2009 - 03/2007)
3. Catherino, William H: 4 articles (03/2010 - 07/2004)
4. Garcia-Closas, Montserrat: 3 articles (04/2014 - 06/2010)
5. Malik, Minnie: 3 articles (03/2010 - 09/2008)
6. Martínez-Alvarez, Concepción: 3 articles (04/2008 - 05/2002)
7. Murray, Jeffrey C: 3 articles (08/2005 - 05/2003)
8. Longaker, M T: 3 articles (07/2001 - 11/2000)
9. Rienhoff, Hugh Young: 2 articles (08/2014 - 08/2013)
10. Brinton, Louise A: 2 articles (04/2014 - 06/2010)

Related Diseases

1. Cicatrix (Scar)
2. Neoplasms (Cancer)
3. Breast Neoplasms (Breast Cancer)
06/01/2011 - "Here associations with risk of invasive breast cancer are assessed for single-nucleotide polymorphisms (SNP) tagging 17 genes in the canonical TGF-β ALK5/SMADs 2&3 and ALK1/SMADs 1&5 signaling pathways: LTBP1, LTBP2, LTBP4, TGFB1, TGFB2, TGFB3, TGFBR1(ALK5), ALK1, TGFBR2, Endoglin, SMAD1, SMAD2, SMAD3, SMAD4, SMAD5, SMAD6, and SMAD7 [Approved Human Gene Nomenclature Committee gene names: ACVRL1 (for ALK1) and ENG (for Endoglin)]. "
05/15/1999 - "Our data support the hypothesis that methylation of a limited number of CpGs at the periphery of an otherwise unmethylated CpG island underlies the transcriptional repression of the downstream promoter in non-breast cancer cells, thereby serving to regulate the use of alternative promoters for TGF-beta3."
11/01/2000 - "The fact that it has been reported previously that high TGF beta 3 plasma levels in patients with untreated early stage breast cancer were correlated with subsequent lymph node metastasis and it was observed in the present study too, that TGF beta 3 expression in breast tumours was an independent predictor of overall survival, led us to suggest that the simultaneous measurement of TGF beta 3 in plasma and its expression in resected tumour tissues in the same cohort of patients may prove to be an important parameter in assessing tumour progression."
10/23/1998 - "Role of transforming growth factor beta3 in lymphatic metastasis in breast cancer."
05/15/1999 - "Activation of an alternative downstream promoter, leading to the production of a truncated mRNA lacking the portion of the 5' noncoding region responsible for translational inhibition of TGF-beta3 mRNA, is only evident in breast cancer cells. "
4. Mucositis
5. Pre-Eclampsia (Preeclampsia)

Related Drugs and Biologics

1. Transforming Growth Factor beta1 (TGF beta 1)
2. Transforming Growth Factor beta (TGF-beta)
3. Transforming Growth Factor beta2
4. Transforming Growth Factors (Transforming Growth Factor)
5. Collagen
6. Fibronectins (Fibronectin)
7. Fluorouracil (Carac)
8. Messenger RNA (mRNA)
9. Protein Isoforms (Isoforms)
10. Intercellular Signaling Peptides and Proteins (Growth Factors)

Related Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Sutures (Suture)
3. Transplants (Transplant)
4. Stents
5. Homologous Transplantation (Allograft)